Related Experiment Video
Updated: May 10, 2025

08:22
Electrowetting-based Digital Microfluidics Platform for Automated Enzyme-linked Immunosorbent Assay
Published on: February 23, 2020
9.4K
Bead-free digital enzyme-linked immunoassay on PDMS microwell array.
Han Wu1, Huaiheng Zhou2, Zhanqiang Sun3
1Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Analytica Chimica Acta
|April 27, 2025
Summary
We developed a low-cost digital enzyme-linked immunoassay (ELISA) using a PDMS microwell array for ultrasensitive protein detection. This bead-free method offers a cost-effective alternative for early disease screening.
Area of Science:
- Biomarker Discovery
- Assay Development
- Microfluidics
Background:
- Low-abundance protein biomarkers are crucial for disease diagnosis but challenging to measure.
- Conventional assays lack sensitivity, while advanced methods are costly and complex.
- A need exists for cost-effective, ultrasensitive protein detection methods.
Purpose of the Study:
- To develop a cost-effective, bead-free digital ELISA platform for ultrasensitive protein detection.
- To overcome limitations of existing ultrasensitive assays, such as high costs and complex fabrication.
Main Methods:
- Fabrication of a polydimethylsiloxane (PDMS) microwell array platform using soft lithography.
- Development of a bead-free digital ELISA within PDMS microwells for immunocomplex formation and separation.
- Modification of the PDMS chip for large-scale femtoliter droplet arrays with minimized evaporation and cross-contamination.
Main Results:
- Achieved ultrasensitive protein detection using the PDMS microwell array digital ELISA.
- Demonstrated significantly reduced costs compared to bead-based digital ELISA methods like SiMoA.
- Successfully applied the platform for single-molecule enzyme and cytokine analysis, with detection limits of 1.57 fM (SβG) and 12.3 fg/ml (IL-6).
Conclusions:
- A straightforward, low-cost PDMS microwell array for digital ELISA was successfully developed.
- The platform enables mass production with minimal batch-to-batch variation.
- This cost-effective and highly sensitive platform shows promise for early disease screening.

